查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1590812

胃肠道药物市场：按分类、疾病类型、给药途径和最终用户分类 - 全球预测 2025-2030

Gastrointestinal Drugs Market by Drug Category (Acid Neutralizers, Anti-Inflammatory, Antiemetic & Antinauseants), Disease Type (Gastroesophageal Reflux Disorder, Irritable Bowel Syndrome), Route of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胃肠道药物市场价值为541.8亿美元，预计2024年将达到572.7亿美元，复合年增长率为5.78%，到2030年将达到803.1亿美元。

胃肠道药物市场广泛集中于治疗各种消化器官系统问题的药物，包括溃疡、发炎发炎性肠道疾病肠道疾病、大肠激躁症和胃食道逆流症。该市场的定义是需要这些药物来控制全球数百万人的症状并改善生活品质。应用范围涵盖医院、诊所和家庭护理机构使用的处方药和非处方药，最终用途为成人和儿童群体。根据市场洞察，胃肠道疾病发病率的增加、老年人口的增加以及药物配方的进步正在推动显着的成长轨迹。然而，严格的监管要求、高昂的药物开发成本和潜在的副作用等挑战是市场扩张的主要障碍。此外，COVID-19 大流行改变了医疗保健分配的优先顺序，影响了非紧急护理的重点和资金筹措。有大量商机可望满足治疗功效和患者依从性方面未满足的需求，例如生技药品和生物相似药的开发、个人化医疗方法以及奈米技术等新型药物输送系统。为了利用这些机会，公司应该投资研发，并专注于既有效又副作用最小的创新解决方案。您还应该考虑建立策略联盟和合作，以加强产品平臺和市场渗透。然而，市场相关人员必须保持对竞争格局的认识，其特征是竞争激烈和技术快速发展。创新和研究的最佳领域包括探索微生物组疗法和人工智慧驱动的患者分层工具，以实现量身定制的治疗计划。市场动态的动态本质需要不断创新来应对新挑战，同时最大限度地提高世界各地患者的治疗价值和可近性。

主要市场统计
基准年[2023] 541.8亿美元
预测年份 [2024] 572.7亿美元
预测年份 [2030] 803.1亿美元
复合年增长率（%） 5.78%

市场动态：揭示快速发展的胃肠道药物市场的关键市场洞察

胃肠道药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口增加，生活方式饮食习惯改变
    • 生技药品的发展和直肠相关疾病的增加
    • 药物开发和意识提高
  • 市场限制因素
    • 与药物相关的副作用
  • 市场机会
    • 加强药物开发的研究和开发活动
    • 治疗过程中的技术进步
  • 市场挑战
    • 缺乏对发炎性肠道疾病肠道疾病和大肠激躁症等疾病的永久性治疗方法；

波特五力：驾驭胃肠道药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胃肠道药物市场的外部影响

外部宏观环境因素对胃肠道药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解胃肠道药物市场竞争状况

对胃肠道药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵胃肠道药物市场供应商绩效评估

FPNV定位矩阵是评估胃肠道药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製胃肠道药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对胃肠道药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人口增加、生活方式和饮食习惯改变
      • 生物製药的开发与直肠相关疾病的增加
      • 药物开发和意识提高
    • 抑制因素
      • 与药物相关的副作用
    • 机会
      • 加强药物开发的研究和开发活动
      • 治疗过程中的技术进步
    • 任务
      • 对于发炎性肠道疾病肠道疾病和大肠激躁症等疾病，没有永久性的治疗方法。
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 胃肠道药物市场（依药物类别）

  • 酸中和剂
  • 发炎（药
  • 止吐和镇痛药
  • 生物製药
  • 泻药/止泻药

第七章胃肠道药物市场：依疾病类型

  • 胃食道逆流症
  • 大肠激躁症

第八章胃肠道药物市场：依给药途径

  • 口服
  • 胃肠外的
  • 直肠

第九章胃肠道药物市场：依最终使用者分类

  • 医院药房
  • 零售药房

第十章美洲胃肠道药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太胃肠道药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲/中东/非洲胃肠道药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • Eli Lilly & Co.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Novo Nordisk A/S
  • Sanofi SA
  • SFJ Pharmaceuticals Group
  • SRS Life Sciences Pte. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Limited
  • ZERIA Pharmaceutical Co.,Ltd.
Product Code: MRR-434CCDA051D0

The Gastrointestinal Drugs Market was valued at USD 54.18 billion in 2023, expected to reach USD 57.27 billion in 2024, and is projected to grow at a CAGR of 5.78%, to USD 80.31 billion by 2030.

The scope of the gastrointestinal drugs market involves a broad focus on medications designed to treat a variety of digestive issues ranging from ulcers, inflammatory bowel disease, irritable bowel syndrome, to gastroesophageal reflux disease. This market is defined by the necessity of these medications to manage symptoms and improve the quality of life for millions of individuals worldwide. Application spans across prescriptions and over-the-counter medications used in hospitals, clinics, and homecare settings, with the end-use scope extending to both adult and pediatric populations. Market insights reveal a significant growth trajectory fueled by rising incidences of gastrointestinal disorders, increasing geriatric populations, and advancements in drug formulations. However, challenges such as stringent regulatory requirements, high costs of drug development, and potential side effects pose significant impediments to market expansion. Moreover, the COVID-19 pandemic has shifted priorities in healthcare allocations, impacting focus and funding toward non-urgent treatments. Opportunities abound in the development of biologics and biosimilars, personalized medicine approaches, and novel drug delivery systems like nanotechnology, which are expected to cater to unmet needs in treatment efficacy and patient compliance. To capitalize on these opportunities, companies should invest in R&D, focusing on innovative solutions that combine efficacy with minimal adverse reactions. They should also consider forging strategic alliances and collaborations to enhance their product pipeline and market reach. However, market players should remain cognizant of the competitive landscape characterized by high rivalry and the fast pace of technological evolution. The best areas for innovation and research include exploration into microbiome therapeutics and AI-driven patient stratification tools, allowing for tailored treatment plans. The nature of the gastrointestinal drugs market is dynamic, demanding continual innovation to address emerging challenges while maximizing therapeutic value and accessibility for patients globally.

KEY MARKET STATISTICS
Base Year [2023] USD 54.18 billion
Estimated Year [2024] USD 57.27 billion
Forecast Year [2030] USD 80.31 billion
CAGR (%) 5.78%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastrointestinal Drugs Market

The Gastrointestinal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing geriatric population, changing lifestyles and eating habits
    • Development in biologics and a rising number of rectal related diseases
    • Drug development and rising awareness
  • Market Restraints
    • Side effects associated with the drugs
  • Market Opportunities
    • R&D activities to enhance drug development
    • Technological advancements in the treatment process
  • Market Challenges
    • Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Gastrointestinal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastrointestinal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastrointestinal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastrointestinal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastrointestinal Drugs Market

A detailed market share analysis in the Gastrointestinal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastrointestinal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastrointestinal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastrointestinal Drugs Market

A strategic analysis of the Gastrointestinal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayer AG, Boehringer Ingelheim GmbH, Eisai Co., Ltd., Eli Lilly & Co., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novo Nordisk A/S, Sanofi S.A., SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Limited, and ZERIA Pharmaceutical Co.,Ltd..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Category, market is studied across Acid Neutralizers, Anti-Inflammatory, Antiemetic & Antinauseants, Biologics, and Laxatives & Anti-diarrheal.
  • Based on Disease Type, market is studied across Gastroesophageal Reflux Disorder and Irritable Bowel Syndrome.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Rectal.
  • Based on End User, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing geriatric population, changing lifestyles and eating habits
      • 5.1.1.2. Development in biologics and a rising number of rectal related diseases
      • 5.1.1.3. Drug development and rising awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D activities to enhance drug development
      • 5.1.3.2. Technological advancements in the treatment process
    • 5.1.4. Challenges
      • 5.1.4.1. Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gastrointestinal Drugs Market, by Drug Category

  • 6.1. Introduction
  • 6.2. Acid Neutralizers
  • 6.3. Anti-Inflammatory
  • 6.4. Antiemetic & Antinauseants
  • 6.5. Biologics
  • 6.6. Laxatives & Anti-diarrheal

7. Gastrointestinal Drugs Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Gastroesophageal Reflux Disorder
  • 7.3. Irritable Bowel Syndrome

8. Gastrointestinal Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Rectal

9. Gastrointestinal Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Retail Pharmacies

10. Americas Gastrointestinal Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gastrointestinal Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gastrointestinal Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bayer AG
  • 3. Boehringer Ingelheim GmbH
  • 4. Eisai Co., Ltd.
  • 5. Eli Lilly & Co.
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Novo Nordisk A/S
  • 9. Sanofi S.A.
  • 10. SFJ Pharmaceuticals Group
  • 11. SRS Life Sciences Pte. Ltd.
  • 12. Sun Pharmaceutical Industries Limited
  • 13. Takeda Pharmaceutical Company Limited
  • 14. Teva Pharmaceuticals Industries Limited
  • 15. ZERIA Pharmaceutical Co.,Ltd.

LIST OF FIGURES

  • FIGURE 1. GASTROINTESTINAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROINTESTINAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GASTROINTESTINAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROINTESTINAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETIC & ANTINAUSEANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES & ANTI-DIARRHEAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023